Products Categories
    Product Certification&
    Enterprise Certification

  • Mr.Xuanming
    Tel: 86 0519 85525329

  • Mobile:15306105585
  • Tel:86 0519 85525329
  • Fax:86 0519 85190960
  • Province/state:Jiangsu
  • City:changzhou
  • Street:China Town, Xinbei, Changzhou, Jiangsu Room 6019
  • MaxCard:
Home > Products >  Cisatracurium Besylate

Cisatracurium Besylate CAS NO.96946-42-8

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,D/A,D/P,T/T,Other
  • Product Details

Keywords

  • Cisatracurium Besylate
  • 96946-42-8
  • C53H72N2O12.2C6H5O3S

Quick Details

  • ProName: Cisatracurium Besylate
  • CasNo: 96946-42-8
  • Molecular Formula: C53H72N2O12.2C6H5O3S
  • Appearance: powder
  • Application: PharmaIntermediate
  • DeliveryTime: within 3-7 day
  • PackAge: As required
  • Port: shanghai or other
  • ProductionCapacity: 5 Metric Ton/Month
  • Purity: 99%
  • Storage: keep in dry and cool condition
  • Transportation: by sea or by air
  • LimitNum: 1 Kilogram

Superiority

Changzhou Xuanming Chemical Co., Ltd. is dedicated to the technology development, manufacturing, import and export chemicals, which are specialized in pharmaceutical intermediates, pesticide intermediate, industry of fine chemicals and custom synthesis. Now, we enjoy good reputation among customers and take favorable market share in domestic and at abroad.

Changzhou Xuanming Chemical CO., LTD is located in Northern Jiangshu Industry Park, we have modern manufacture bases and some laboratories, which can supply the key intermediate for your projects, and short your synthesis scheme and supply you a reference compound for bioassay or a high purity analytical standard. We have been abided by “treat technology as first, quality as basis, customers as God, and be honest and sincere”. It is our final aim to provide environmental and high technological products and meet customers’ requirements according to keep effors on developing new chemical fields.

Changzhou Xuanming Chemical CO., LTD promises to help you with heart and soul.

Details

Cisatracurium besylate Basic information
Muscle relaxants Pharmacological effects Pharmacokinetics Clinical application Cisatracurium Besilate Dosage Suitable solvents Rate of administration Stability Side effects Taboo and caution Drug Interactions
Product Name: Cisatracurium besylate
Synonyms: Atracurium Impurity 1（Cisatracurium Besilate）;Cisatrcurium Besylate;3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propionic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl ester;5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate;Cisatracurium besyla;Cisatracurium bes (Cisatracuriumbesylate/Clotrimazole);Cis-AttacuriuM;(1R,1'R,2R,2'R)-
CAS: 96946-42-8
MF: C53H72N2O12.2C6H5O3S
MW: 1243.49
EINECS: 620-579-9
Product Categories: -;Neuromuscular Blocking Agent;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs;Analgesic series
Mol File: 96946-42-8.mol
Cisatracurium besylate Structure
 
Cisatracurium besylate Chemical Properties
Melting point  90-93°C
storage temp.  Amber Vial, -20°C Freezer, Under Inert Atmosphere
solubility  H2O: soluble1mg/mL
color  white
 
Safety Information
Hazard Codes  T
Risk Statements  25-36
Safety Statements  45
RIDADR  UN 2811 6.1 / PGIII
WGK Germany  3
HS Code  29145090
MSDS Information
 
 
Cisatracurium besylate Usage And Synthesis
Muscle relaxants Cisatracurium besylate is the benzene sulfonate salt form of atracurium. It is a kind of artificially synthetic non-depolarizing muscle relaxants with its role similar as tubocurarine. It has an onset time of 1 minute and duration time of 15 minutes. The treatment dose does not affect the heart, liver and kidney function. It also has no accumulation property. It also can induce the release of histamine when used at large doses. For muscle relaxation or breathing control required in surgery, compared with current clinical major muscle-relaxing anesthetic drugs, cisatracurium besylate is not metabolized through liver or kidney, and has cardiovascular stability; its effect of muscle relaxation is 3 times as strong as atracurium without any cardiovascular side effects. Cisatracurium besylate is mainly applied to general anesthesia, and can be widely used in intubation, treating liver and kidney dysfunction, used in cardiovascular surgery and elderly and pediatric patients. 
Compared with atracurium, this product has no dose-dependent adverse effects of histamine release; however, the disadvantage is that patients with liver and kidney dysfunction should administrate with caution. 
Since 1996 for the first time when this drug has entered into market in UK, foreign countries have gradually applied it to replace vecuronium and atracurium as the mainstream of clinical muscle relaxants.
Pharmacological effects The mechanism of action of cisatracurium besylate is similar with that of tubocurarine chloride; but this product is a kind of non-depolarizing muscle relaxant drugs which is mainly used for blocking the transmission of nerve impulses, boost muscle relaxation and can release histamine; but it has a lower effect than tubocurarine alkaline; it is characterized by a rapid onset and a high muscle relaxant effect.
Pharmacokinetics After its intravenous injection of the product into the body tissue, it rapidly play a pharmacological effect in the target, and can further pass through the placenta into the fetal circulation.
Clinical application Clinically, it is generally used for maintaining muscle relaxing or facilitating the mechanical respiration; larger doses can be used for endotracheal intubation.
Cisatracurium Besilate Cisatracurium besylate is one of the 10 kinds of isomers of atracurium, accounting for about 15% of the total mixture of ammonium atracurium. Like the case of the its parent compound, it also belongs to benzyl isoquinoline non-depolarizing muscle relaxants. Cisatracurium besylate has a ED95 of 0.05 mg/kg; the muscle relaxation potency of it is 3 to 5 times as high as that of atracurium. It has a low lipid-solubility, and is not directly subject to the hydrolysis of nonspecific esterase in plasma; 80% is inactivated by Hofmann degradation with no effect of histamine release as well as a low incidence of allergic reactions. Clinical data has shown that the rapid intravenous injection of 8 × ED95 amount of cis-atracurium to healthy patients undergoing elective surgery rapid intravenous injection causes no signs of histamine release. On contrary, only 2 × ED95 amount of atracurium is enough to induce a histamine release effect. It only has a slight influence on cardiovascular function, and it has only a few metabolites. The effect of the decomposition products of cis-atracurium, N-laudanosine is only about 1/3 to 1/10 of that of equal dose of atracurium dose. From this angle, long-term application will not result in convulsion caused by high plasma concentration. It can be used for endotracheal intubation and maintaining muscle relaxation during anesthesia, especially be suitable for patients suffering liver and kidney dysfunction who are undergoing anesthesia.
Dosage It can be intravenously injection or dropping without local injection. The dose is decided by the weight as well as the surgery requirement of the patients. Adult conventional dose: before induction of anesthesia medication (such as propofol) for intubation, take 0.15 mg/kg of this product (about 10mg/10mL) for intravenous injection within 1~1.5 min and can achieve good intubation efficacy in 2 min; for maintaining the muscle relaxing during the surgery, injecting 0.03mg/kg per time for maintaining muscle relaxing for about 20min. Intravenous dropping: for maintaining muscle relaxing, first apply a dose of 0.18mg/(kg • h) for administration until a steady state is reached, change to 1~2mg/(kg • min) which can mostly achieve sustained muscle relaxation state.
Suitable solvents 0.9% sodium chloride injection liquid, 5% dextrose injection or sodium chloride (0.45%) combined with glucose (2.5%).
Rate of administration Intravenous administration: When used for endotracheal intubation, inject within 1~1.5 min. Intravenous dropping: according to the situation of muscle relaxing and the dose controlling, when the steady state of muscle relaxation is reached, a rate of 0.1 mg/min is suitable for the average adult (60kg) for maintaining muscle relaxing.
The above information is edited by the chemicalbook of Dai xiongfeng.
Stability For storage, it should be sealed, kept in dark and preserved at 2~8 °C; avoid freezing. Original injection exhibits pale yellow to yellow-green and clean. It can be stored at room temperature for 3 to 6 weeks. After unsealing and dilution for more than 24h, it is not suitable for re-applying.
Side effects As one kind of the combined anesthesia drugs; it had ever caused a kind of rarely but seriously allergic reaction. Common adverse reactions include visible rash, flushing, hypotension, bradycardia, and bronchospasm.
Taboo and caution People who are allergic to this product or atracurium should be prohibited for applying. Patients of renal insufficiency, electrolyte imbalance, low body temperature, neuromuscular disease, cancer, and cachexia should apply with caution.
Drug Interactions 1. when combined with a variety of anesthetics, ganglion blockers (such as six methylamine), potent diuretics, antiarrhythmic drugs, and other polypeptide antibiotics tetracycline, the muscle relaxation effect can be extended or strengthened. 
2. Drug which can interfere with potassium, magnesium, lithium salt balance, and potassium releasing hormones can change the muscle relaxing effect of this product. 
3. the application of succinylcholine can cause that the drug’s effect can’t be antagonized by neostigmine.
Description Cisatracurium besylate is a new intermediate-duration non-depolarizing muscle relaxant launched in the U.S.A. for intubation and maintenance of muscle relaxation during surgery and intensive care. Cisatracurium besylate is the single 1 R cis-1'R cis isomer of the commercial preparation of atracurium, a mixture of 10 isomers. It is 3 to 5 times more potent than the mixture with similar onset and duration of action. The single isomer was also reported to have reduced propensity to release histamine and have a stable cardiovascular profile. Similar to structurally related mivacurium, cisatracurium has distinct advantages of rapid degradation, enzymatic metabolism that is independent of liver or kidney resulting in short duration of action and fast, complete recovery.
Chemical Properties White Solid
Originator Glaxo Wellcome (United Kingdom)
Uses Cisatracurium Besylate is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.
Uses An enantiomer of Atracurium Besylate (A794500). A neuromuscular blocking agent. It could be used in liver transplant patient with safety.
Definition ChEBI: The (1R,1'R,2R,2'R)-diastereoisomer of atracurium besylate. Commercial preparations of atracurium are mixtures of 10 stereoisomers, of which cisatracurium generally constitutes about 15%. isatracurium besylate is about 3 times more potent than the mixture of atracurium isomers as a neuromuscular blocking agent, and is used as a muscle relaxant for endotracheal intubation, to aid controlled ventilation, and in general anaesthesia.
Brand name Nimbex (Abbott).

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog